6 unknown, 2 completed, 2 recruiting. 3 Phase 2, 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Unknown 3 |
| Phase 3 | 3 | Completed 1, Recruiting 1, Unknown 1 |
Follow Docetaxel: new trials by email Literature Review of Docetaxel trials Research Report on Docetaxel
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Prospective Observational Study of Outcomes After Gemcitabine, Docetaxel, Melphalan, and Carboplatin With Autologous Stem Cell Transplantation in Pediatric Relapsed/Refractory Germ Cell Tumors Gemcitabine (GEM), Docetaxel, Melphalan - Prospective Observational Study, Gemcitabine | Recruiting | M.D. Anderson Cancer Center | 30 | 2026-06-05 | 2026-06-23 | |
| Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer Oxaliplatin plus S-1, Docetaxel plus S-1 - Gastric Cancer (GC), Adjuvant Chemotherapy | Phase 3 | Recruiting | Ruijin Hospital | 387 | 2025-12-15 | 2026-01-26 |
| Sequential Intravesical Gemcitabine and Docetaxel for Rescue Therapy in BCG Unresponsive Non-muscle Invasive Bladder Cancer Patients Intravesical Solution - Bladder Cancer, BCG | Unknown | Dokuz Eylul University | 120 | 2024-04-09 | 2024-04-19 | |
| A Bioequivalence Study of Docetaxel Injection in Patients With Solid Tumours BH009 (Docetaxel injection), Docetaxel injection - Docetaxel, Solid Tumours | Phase 3 | Completed | Zhuhai Beihai Biotech Co., Ltd | 46 | 2021-04-29 | 2022-01-11 |
| Interest of the Addition of Docetaxel to Standard Treatment in First-line Advanced HER2 Positive Gastroesophageal Adenocarcinoma in Selective Patients Taxane - HER2-positive Gastric Cancer, Metastatic Cancer | Completed | Centre Hospitalier Universitaire de Besancon | 65 | 2021-04-01 | 2021-06-10 | |
| A Study of Nivolumab +/- Docetaxel in Patients Previously Treated With Advanced or Metastatic NSCLC Nivolumab - Carcinoma, Non-Small-Cell Lung, Docetaxel | Phase 2 | Unknown | Peking University Cancer Hospital & Institute | 72 | 2019-07-08 | 2019-07-17 |
| FOLFIRINOX vs FLOT Chemotherapy for Resectable Gastric or Esophagogastric Junction Adenocarcinoma Irinotecan, 5-FU, Leucovorin - Stomach Neoplasms, Gastrointestinal Neoplasms | Phase 2 / Phase 3 | Unknown | Blokhin's Russian Cancer Research Center | 538 | 2019-01-29 | 2021-04-13 |
| Anlotinib Plus Chemotherapy for Patients With Advanced Non-small Cell Lung Cancer anlotinib plus chemotherapy, chemotherapy - Lung Neoplasms, Docetaxel | Phase 2 | Unknown | The First People's Hospital of Lianyungang | 60 | 2018-08-01 | 2018-07-18 |
| Association of Genetic Polymorphisms With Docetaxel-based Chemotherapy Toxicities in Chinese Solid Tumor Patients detection of genotype - Solid Tumors, Docetaxel | Unknown | Cui Yimin | 2200 | 2017-09-25 | 2019-08-28 | |
| PROSTAC: Prospective Multi-centre Study of Prognostic Factors in mCRPC Patients Treated With Docetaxel or Cabazitaxel. Advanced Prostate Cancer, Cabazitaxel | Unknown | Centro Nacional de Investigaciones Oncologicas CARLOS III | 402 | 2014-05-01 | 2020-01-27 |
Stomach Neoplasms (2) · Carcinoma, Non-Small-Cell Lung (1) · Drug-Related Side Effects and Adverse Reactions (1) · Gastrointestinal Neoplasms (1) · Lung Neoplasms (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (5) · Neoplasms by Site (5) · Digestive System Diseases (2) · Digestive System Neoplasms (2) · Gastrointestinal Diseases (2) · Lung Diseases (2) · Respiratory Tract Diseases (2) · Respiratory Tract Neoplasms (2) · Stomach Diseases (2) · Thoracic Neoplasms (2) · Bronchial Neoplasms (1) · Carcinoma, Bronchogenic (1) · Chemically-Induced Disorders (1) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1)
Docetaxel (6) · Oxaliplatin (2) · Carboplatin (1) · Drug Therapy (1) · Fluorouracil (1) · Gemcitabine (1) · Injections (1) · Irinotecan (1) · Leucovorin (1) · Melphalan (1) · Nivolumab (1) · S 1 (combination) (1) · anlotinib (1) · taxane (1)
Blokhin's Russian Cancer Research Center (1) · Centre Hospitalier Universitaire de Besancon (1) · Centro Nacional de Investigaciones Oncologicas CARLOS III (1) · Cui Yimin (1) · Dokuz Eylul University (1) · M.D. Anderson Cancer Center (1) · Peking University Cancer Hospital & Institute (1) · Ruijin Hospital (1) · The First People's Hospital of Lianyungang (1) · Zhuhai Beihai Biotech Co., Ltd (1)
China (4) · France (1) · India (1) · Russia (1) · Spain (1) · Turkey (Türkiye) (1) · United States (1)
David Olmos, MD, PhD (1) · Gopichand M, Ph. D. (1) · Irtiza N Sheikh, MD (1) · Ivan Stilidi, PhD (1)